The World Health Organization warned on Monday that 73 countries face possible stock-outs of antiretroviral HIV medicines because of COVID-19 disruptions, with 24 countries already reporting critically low supplies — a shortfall that could double AIDS-related deaths in sub-Saharan Africa this year if treatment access is interrupted for six months.
The warning comes from a WHO survey published ahead of the International AIDS Society’s biannual conference, which opened this week. WHO reported that suppliers have failed to deliver antiretroviral (ARV) medicines on time, that land and air transport has shut down, and that patients cannot always reach health services inside their own countries.
Why could a supply gap double deaths?
The arithmetic behind the warning comes from a modelling exercise convened by WHO and UNAIDS in May. It forecast that a six-month disruption in ARV access could double AIDS-related deaths in sub-Saharan Africa in 2020 alone.
The scale at stake is large. In 2019, an estimated 8.3 million people were taking ARVs in the 24 countries now reporting shortages — about one third of everyone on HIV treatment globally. These medicines do not cure HIV, but they suppress the virus and prevent onward sexual transmission.
“The findings of this survey are deeply concerning,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Countries and their development partners must do all they can to ensure that people who need HIV treatment continue to access it. We cannot let the COVID-19 pandemic undo the hard-won gains in the global response to this disease.”
Supplying antiretroviral therapy prevents viral rebound
- Antiretroviral therapy keeps HIV suppressed; stopping it lets the virus rebound and weakens the immune system, which is why a supply gap is a life-or-death issue, not a convenience problem.
- Roughly one in three people on HIV treatment worldwide lives in one of the 24 countries now reporting critically low stocks or supply disruptions.
- A proven workaround already exists: “multi-month dispensing,” which lets patients collect up to six months of medicine in one visit, cutting the number of trips to clinics during the pandemic.
How far has the AIDS response stalled?
Data released by UNAIDS and WHO on Monday show two decades of hard-won progress now flattening. New HIV infections fell 39% between 2000 and 2019, HIV-related deaths fell 51%, and antiretroviral therapy saved some 15 million lives over that period.
But the last two years tell a different story. Annual new infections have plateaued at 1.7 million, and HIV-related deaths dropped only modestly, from 730 000 in 2018 to 690 000 in 2019. More than 25 million people in need of ARVs received them in 2019, yet WHO reported that key 2020 global targets will be missed, with prevention and testing services not reaching the groups that need them most.
Which numbers define the setback?
| Indicator | Figure | Period / Group |
|---|---|---|
| Countries with critically low stock or disruption | 24 | WHO survey, 2020 |
| People on ARVs in the 24 affected countries | 8.3 million (about 33% of global treatment) | 2019 |
| New HIV infections annually | 1.7 million (plateaued) | Last two years |
| HIV-related deaths | 730 000 → 690 000 | 2018 → 2019 |
| Children receiving needed ART | 53% | 2019 |
What are countries doing to keep medicines flowing?
WHO has issued guidance on maintaining essential health services during the pandemic, including for people living with or affected by HIV. Its centerpiece for HIV is multi-month dispensing — prescribing medicines for up to six months at a time — which 129 countries have now adopted, WHO reported.
Countries are also working to keep flights and supply chains running, engaging communities to deliver HIV medicines, and negotiating with manufacturers to overcome logistics challenges.
Why does children’s HIV treatment lag behind?
One gap the WHO material highlights is pediatric. In 2019 there were an estimated 95 000 HIV-related deaths and 150 000 new infections among children, and only about half — 53% — of children needing antiretroviral therapy were receiving it. A longstanding barrier: few optimal medicines come in formulations suitable for young children.
“Through a collaboration of multiple partners, we are likely to see generic versions of dolutegravir for children by early 2021, allowing for a rapid reduction in the cost of this medicine,” said Dr Meg Doherty, Director of the Department of Global HIV, Hepatitis and STI Programmes at WHO. “This will give us another new tool to reach children living with HIV and keep them alive and healthy.”
WHO said it is fast-tracking prequalification of DTG as a generic drug so countries can use it as soon as possible.
What about the infections that kill people with HIV?
Many HIV-related deaths come from opportunistic infections — bacterial, viral, parasitic and fungal diseases that exploit a weakened immune system. WHO listed tuberculosis and hepatitis among them, along with COVID-19, toxoplasmosis and histoplasmosis.
Contact clinics if ARV refills are unavailable
People living with HIV who cannot obtain their usual ARV refill should contact their clinic or national HIV programme immediately rather than interrupting therapy on their own — WHO’s guidance urges countries to prevent exactly these treatment interruptions.
Patients who develop persistent fever, cough, or weight loss should seek evaluation for opportunistic infections such as tuberculosis or, in the Americas region, histoplasmosis, which the new WHO guidelines address. Dolutegravir’s new pediatric formulation is approved for infants older than 4 weeks and above 3 kg; dosing decisions belong with the treating clinician.
Where does the response go from here?
The immediate priorities WHO laid out are keeping treatment flowing through multi-month dispensing and community delivery, and reinvigorating prevention and testing with better targeting of the populations most affected. The IAS conference this week is the venue where WHO will press the case for stepping up services for children and other disproportionately affected groups.
As Tedros put it: “We cannot let the COVID-19 pandemic undo the hard-won gains in the global response to this disease.”
References
- World Health Organization — news release: HIV access severely impacted by COVID-19 as AIDS response stalls (July 6, 2020)
- WHO/UNAIDS modelling exercise, May 2020: The cost of inaction — COVID-19-related service disruptions could cause hundreds of thousands of extra deaths from HIV
- WHO guidance: Maintaining essential health services during the COVID-19 outbreak
- UNAIDS/WHO 2020 global HIV data released July 6, 2020